Eli Lilly loses Alimta drug patent case in Germany to Actavis

March 6, 2015 1:52 PM

19 0

(Reuters) - Eli Lilly has lost a patent case in Germany over its blockbuster Alimta lung cancer drug to generic producer Actavis, hitting the U.S. drugmaker's future sales hopes for the medicine.

Alimta generated worldwide sales of $2.79 billion for Lilly last year, making the medicine its biggest-selling product.

Also read: Louboutin wins fight to prevent red sole copycats

Read more

To category page